Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Despite the more optimistic side of all of us yearning to get back to $30 or more, I believe if Amgen or anyone put in a tender offer to acquire ADXS for $15 tomorrow, it would easily be accepted by both our Board and our majority of investors, because frankly ADXS has had four years under the recapitalized company to get us to a higher base that would set the stage for a buyout at a higher value but has failed. I don't think our investor base is willing to risk another four years that could be a repeat of the last four in which investors poured more than $200 million into the company at an average $12 price only to see their investment fall to the present level. Some key investors have already bailed such as Broadfin, Pictet and T Rowe.

So our interim-CEO is an M&A guy and he will be the interim CEO for the foreseeable future. Putting the pieces together I bet there's a good chance we never get a permanent CEO and that Lombardo's task is two-fold: 1) first srike a large licensing deal on Europe and/or HER2 and/or HOT to get our valuation up, then 2) sell the company outright say at a 100% premium to the higher base valuation following whatever deal(s) he strikes.